Why Both Treatments Are Available Now at EverydayMeds
Wegovy vs Mounjaro In Stock Availability in the UK
The question of whether Wegovy is better than Mounjaro often centres on immediate availability, particularly given historical supply challenges with Wegovy. At EverydayMeds, we maintain comprehensive stock of both treatments through direct partnerships with Novo Nordisk and Eli Lilly respectively. Our reliable supply chain means you can access either treatment without joining waitlists or experiencing delays that have previously frustrated patients seeking weight management support.
All five Wegovy doses are currently in stock and ready for next-day delivery once your prescription is approved by our clinical team. This includes the complete dose escalation pathway from 0.25mg starter through to 2.4mg maintenance, ensuring continuity of treatment without interruption. Similarly, our Mounjaro stock covers the full tirzepatide range, giving you and your prescriber genuine choice rather than settling for whatever happens to be available.
Pricing Comparison: Wegovy Better Value Than Mounjaro for UK Patients
When comparing whether Wegovy offers better value than Mounjaro, the pricing structure reveals significant differences. Wegovy starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg) to £209.99 for the 2.4mg maintenance dose. Our bundle options like the Intro Trio (0.25mg, 0.5mg & 1mg) at £299.99 provide convenient three-month starter packages. New customers apply code FIRST40 at checkout to reach these prices, whilst returning customers use DOSE25.
Mounjaro pricing follows a different structure reflecting its dual-agonist formulation, typically commanding a premium over single-mechanism treatments. Both treatments represent prescription-only medicines requiring clinical assessment, but the Wegovy pricing pathway offers more predictable cost progression through the dose escalation phases. The ability to order both treatments through our streamlined process means your choice isn't constrained by availability or insurance considerations that affect other supply channels.
Clinical Evidence: Wegovy vs Mounjaro Effectiveness Comparison
Clinical trials suggest both treatments can support significant weight management alongside reduced-calorie diet and increased physical activity, though direct head-to-head comparisons remain limited. Wegovy's STEP trials demonstrated that patients achieved approximately 15% average weight loss at 68 weeks in STEP 1, with sustained results of 15.2% at two years in STEP 5 (Wilding et al., NEJM, 2021). The SELECT trial additionally showed a 20% reduction in major cardiovascular events, indicating benefits beyond weight management.
Mounjaro's mechanism as a dual GIP/GLP-1 receptor agonist theoretically offers enhanced metabolic effects compared to Wegovy's single GLP-1 targeting approach. However, comparing trial percentages directly would be misleading due to different study designs, patient populations, and endpoints. Both treatments require the same commitment to lifestyle modifications and represent long-term weight management strategies rather than short-term interventions.
How Wegovy Works Differently from Mounjaro
Understanding whether Wegovy is better than Mounjaro requires appreciating their distinct mechanisms of action within your body's weight regulation systems. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural incretin hormone, primarily targeting appetite control centres in the brain and slowing gastric emptying. This single-pathway approach creates reliable feelings of fullness after smaller meals and may reduce food cravings by modulating reward pathways associated with eating behaviour. The once-weekly injection delivers consistent semaglutide levels, maintaining appetite suppression throughout the dosing interval. Wegovy's mechanism has been extensively studied across multiple patient populations, providing robust evidence for its weight management effects when combined with lifestyle modifications.
Streamlined Ordering Process for Both Treatments
Accessing either Wegovy or Mounjaro through EverydayMeds follows our standardised three-minute online clinical assessment, designed to evaluate your suitability for prescription weight management medications. Our qualified prescribers review your assessment within three working days (or 24 hours with express service), considering your BMI, medical history, current medications, and previous weight management attempts. Once approved, your chosen treatment ships via next-day delivery using temperature-controlled packaging that maintains the cold-chain integrity essential for these biological medicines. Our GPhC-registered pharmacy status (#9012878) ensures all prescribing and dispensing meets UK regulatory standards. The entire process eliminates traditional pharmacy visits whilst maintaining clinical safety and regulatory compliance.
Storage and Practical Considerations: Wegovy vs Mounjaro
Practical storage differences often influence treatment choice, particularly for patients who travel frequently or live in warmer climates. Wegovy offers superior room-temperature stability, remaining effective for up to six weeks when stored below 30°C after removal from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both treatments require refrigeration at 2-8°C before first use, but Wegovy's extended ambient stability provides greater flexibility for holidays, business travel, or temporary storage challenges. The FlexTouch pen delivery system used for Wegovy features intuitive dose selection and injection mechanisms, whilst both treatments follow weekly injection schedules that fit easily into most lifestyle routines. Dose escalation is mandatory for both treatments, starting at low doses to minimise side effects before reaching therapeutic levels.
Why Wegovy Availability Matters More Than Mounjaro Shortages
The historical context of Wegovy supply shortages makes current in-stock availability particularly valuable for UK patients comparing these treatments. Unlike previous periods when patients faced months-long waitlists, our current Wegovy inventory includes all dose strengths with reliable replenishment schedules directly from Novo Nordisk manufacturing. This stability means you can commit to the full 16-week dose escalation pathway without uncertainty about accessing higher doses when clinically appropriate.
Mounjaro has generally maintained better supply consistency, but Wegovy's return to full availability levels the playing field for treatment selection. Having both options readily available means your choice can focus on clinical suitability, mechanism preference, and practical considerations rather than settling for whichever treatment happens to be accessible. This availability particularly benefits patients who have researched both options and developed preferences based on their individual circumstances and treatment goals.
Making Your Decision: Wegovy vs Mounjaro with Expert Support
Rather than determining whether Wegovy is definitively better than Mounjaro, the optimal choice depends on your individual medical profile, lifestyle requirements, and treatment preferences. Both treatments are available from EverydayMeds with equivalent clinical oversight, delivery standards, and ongoing support throughout your weight management journey. Our clinical team can help evaluate factors like your response to previous GLP-1 medications, travel requirements that favour Wegovy's storage stability, or preferences for single versus dual-mechanism approaches. The prescription-only nature of both treatments ensures you receive personalised clinical assessment regardless of which option you select. Begin your assessment today using discount codes FIRST40 (new customers) or DOSE25 (returning customers) at https://everydaymeds.co.uk/collections/wegovy and discuss with our prescribers which treatment best aligns with your weight management objectives.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
